Thrombin inhibitors
The development of a thrombus, initiated by the formation of thrombin as the final stage of the coagulation cascade, is the major triggering mechanism in many acute ischaemic syndromes.' 2 Thrombin formation has three major effects: * Generation of more thrombin through a positive feedback loop * Formation of fibrin * Activation of thrombocytes leading to aggregation and release of various vasoconstrictive and procoagulant factors. Specific thrombin inhibitors block these effects, thus preventing or reducing both fibrin formation and thrombocyte aggregation (figure). The new generation of thrombin inhibitors include direct derivatives of hirudin, isolated from the leech Hirudo medicinalis, such as recombinant hirudin (a 65 amino acid polypeptide) and hirulog (a 20 amino acid peptide) as well as other synthetic compounds, including hirugen, argatroban, and efegatran. [3] [4] [5] Though the thrombin inhibitors are often compared to heparin and like heparin can be given intravenously or subcutaneously, their mechanism of action is quite differ- Activation offactor X induces thrombin formation in three major ways: formation offibrin, generation of morefibrin through positive feedback, and activation of thrombocytes. Platelet membrane receptors include the glycoprotein (GP) Ia receptor binding to collagen (C), GP Ib to von Willebrand factor (vWF), and GP IIblIIIA which binds to different macromolecules includingfibrinogen ent. Heparin inhibits thrombin formation, but its pharmacological activity is less specific than that of these new drugs. Among other factors, heparin requires antithrombin III, and it cannot inactivate clot-bound thrombin. Heparin can be inactivated by plasma proteins and platelet factor 4, and it has other effects in addition to its anticoagulant properties, including inhibition of platelet function and inhibition of proliferation of vascular smooth muscle cells.6 In contrast, the new compounds are specific direct inhibitors of both free and clot-bound thrombin.
Heparin can be neutralised with protamine sulphate, but as yet the specific thrombin inhibitors have no antidote. Accordingly, this new class of drugs may be less suitable when the anticoagulation effect needs to be rapidly reversed-for example, during cardiac surgery. Nevertheless, the longest acting thrombin inhibitors have a half life of no more than a few hours, and when the infusion of the drug is stopped normal coagulation is quickly restored.
It is not certain how the optimal dose of specific thrombin inhibitors should be determined. Heparin dosing is adjusted according to measurement of activated partial thromboplastin time (aPI-T) or activated clotting time (ACT). The tokinase revealed no major safety issues.14 15 However, in three subsequent larger studies an excess of major bleeding, in particular intracranial bleeds, was seen in patients treated with a high dose of hirudin combined with thrombolytic treatment (table 1) .16-18 The overall rate of intracranial haemorrhage with hirudin was 2-2%. Other bleeding complications were also more frequent in patients receiving hirudin. Surprisingly, in two studies (GUSTO IIa and TIMI 9A) an unexpected excess of intracranial haemorrhage was also seen in patients receiving heparin in conjunction with thrombolytic treatment. This illustrates the narrow therapeutic range of combined thrombolytic and anticoagulant treatment. In fact, the heparin dosages in GUSTO Ila and TIMI 9A were only slightly higher than in previous studies. After extensive consultation two trials have been restarted-GUSTO IIb and TIMI 9B-both with a more prudent heparin regimen, and with a much lower dose of hirudin, which was reduced from a bolus of 0-6 mg/kg and an infusion of 0-2 mg/kg/h to a bolus of 0-1 mg/kg followed by an infusion of 041 mg/kg/h. Another option might have been to reduce the dose of the thrombolytic agent, and further studies are needed to determine the optimal dosages for combination treatment in patients with evolving myocardial infarction.
If the results of ongoing trials with hirudin and with other thrombin inhibitors are favourable, it is likely that the specific inhibitors will replace heparin for many indications, provided that their costs are not prohibitive. The current generation of specific thrombin inhibitors must be given parenterally. It is, however, possible that synthetic thrombin inhibitors will be developed for oral use Presently, IIb/IIIa receptor blockers are available for intravenous use only, and their use is therefore restricted to patients in hospital. Oral compounds are being developed. If these were successful, they might replace aspirin for the long-term treatment of coronary artery disease, provided that they did not cost too much.
Combined application Potentiation between thrombin inhibitors and IIb/IIIa receptor blockers has been seen in animal experiments.28 A combination of these compounds may become the preferred treatment. Similarly, in animal experiments thrombolysis was enhanced by addition of a IIb/IIIa receptor blocker to thrombocyte agents.29 Because such combinations could induce excessive bleeding careful studies are needed to determine the optimal dose combinations of these drugs for various groups of patients.
Different types of patients may need different approaches. In particular decisions on the level of anticoagulation or a decision to combine specific antithrombins with the IIb/IIIa receptor blockers might be based on the expected thrombotic risk in each patient.
Myocardial infarction
The risk of mortality and other complications in patients with myocardial infarction can be estimated from baseline characteristics including elderly age, a history of previous infarction, a large area at risk, and the presence of heart failure. Both the short and long-term benefits of thrombolytic treatment are directly proportional to the level of the baseline risk.30 Thus more intense treatment may be warranted in patients at a higher risk of mortality. In such patients, a combination of thrombolytic treatment with specific thrombin inhibitors and IIb/IIIa receptor blocker may be appropriate, even if such combination carries a higher bleeding risk. On the other hand, in subgroups of patients at low risk in whom the benefit of treatment is expected to be small, bleeding risk should be reduced and the mode and intensity of anticoagulant treatment should be adapted accordingly. Chronic ambulatory treatment Most patients in whom coronary artery disease has been diagnosed, particularly those with angina and survivors of myocardial infarction, are currently treated with aspirin. Although indirect evidence suggests that the coumadin agents may be more effective, at least in myocardial infarction survivors,33 most clinicians favour the much cheaper and easier to use thrombocyte aggregation inhibitor. As specific oral thrombin inhibitors and/or specific receptor blockers become available, these may be prescribed to prevent thrombotic complications in these patients, and also after cardiac surgery and in those with atrial fibrillation, deep venous thrombosis, pulmonary embolism, and after vascular surgery. Again, the intensity of treatment could be tailored to the expected rate of thrombotic complications. More intensive treatment could be given in the first months after myocardial infarction or shortly after a period of unstable angina. Cigarette smoking, associated with activated coagulation, could also be considered as an indication for more intense coagulation. Treatment could be less intense in other circumstances, for instance during the first 6 months after an acute ischaemic event, and in elderly patients, who are at greater risk of bleeding complications. 
Conclusions

